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Abstract
Background: Impaired mobility is a cardinal feature of multiple sclerosis (MS) and is rated by people with MS as
their highest priority. By the secondary progressive phase, balance, mobility and physical activity levels are significantly
compromised; an estimated 70% of people with secondary progressive MS fall regularly. Our ongoing research has
systematically developed ‘Balance Right in MS’ (BRiMS), an innovative, manualised 13-week guided self-management
programme tailored to the needs of people with MS, designed to improve safe mobility and minimise falls. Our eventual
aim is to assess the clinical and cost effectiveness of BRiMS in people with secondary progressive MS by undertaking an
appropriately statistically powered, multi-centre, assessor-blinded definitive, randomised controlled trial. This feasibility study
will assess the acceptability of the intervention and test the achievability of running such a definitive trial.
Methods/design: This is a pragmatic multi-centre feasibility randomised controlled trial with blinded outcome assessment.
Sixty ambulant people with secondary progressive MS who self-report two or more falls in the previous 6 months will be
randomly allocated (1:1) to either the BRiMS programme plus usual care or to usual care alone. All participants will be
assessed at baseline and followed up at 15 weeks and 27 weeks post-randomisation.
The outcomes of this feasibility trial include:
 Feasibility outcomes, including trial recruitment, retention and completion
 Assessment of the proposed outcome measures for the anticipated definitive trial (including measures of walking,
quality of life, falls, balance and activity level)
 Measures of adherence to the BRiMS programme
 Data to inform the economic evaluation in a future trial
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 Process evaluation (assessment of treatment fidelity and qualitative evaluation of participant and treating therapist
experience)
Discussion: The BRiMS intervention aims to address a key concern for MS service users and providers. However, there are
several uncertainties which need to be addressed prior to progressing to a full-scale trial, including acceptability of the
BRiMS intervention and practicality of the trial procedures. This feasibility trial will provide important insights to resolve
these uncertainties and will enable a protocol to be finalised for use in the definitive trial.
Trial registration: ISRCTN13587999.
Keywords: Secondary progressive multiple sclerosis, Exercise, Self-management, Mobility, Accidental falls, Balance, Quality
of life, Feasibility randomised controlled trial
Background
Multiple sclerosis (MS) affects approximately 100,000
people in the UK [1], with an estimated cost of £1.4 bil-
lion/annum to the National Health Service (NHS) and
wider society [2]. Although most people start with a
relapsing-remitting (RR) disease course, approximately
two thirds move to a secondary progressive phase within
8 years [3]. At this point, medical interventions are
limited and progression is inevitable [4].
Surveys of people with MS (pwMS) consistently rank
mobility as their highest priority and most important yet
most challenging daily function [5]. Evaluation of treat-
ments to improve mobility has also been highlighted as
one of the top 10 MS research priorities by the James
Lind Alliance [6]. Impaired balance and falls are
common issues for people with secondary progressive
MS (SPMS) and are an important contributory factor to
mobility impairment [7, 8]. Approximately 70% of pwMS
fall regularly [9, 10], at an average rate of >26 falls/per-
son/year in SPMS [11]. More than 10% of these falls lead
to injuries [12] and pwMS are three times more likely to
sustain a fracture than the general population [13].
Falling and fear of falling have a profound impact on
individuals, leading to activity curtailment, social isola-
tion and a downward spiral of immobility, decondition-
ing and disability accumulation [14]. There are also
substantial economic and social costs related to increas-
ing immobility, impaired balance and falls in pwMS [15].
Costs of health and social care have been shown to
increase steeply with increasing disease severity/immo-
bility, underlining the importance of optimising safe
mobility for as long as possible [16]. This is particularly
relevant given evidence that pwMS are living longer,
leading to a rising population living with the disease
[17]. This has important implications for resource
provision, as highlighted in a national audit of neuro-
logical services [18].
The importance of mobility and falls is further empha-
sised by their consistent prominence in policy docu-
ments for long-term neurological conditions [19]. Work
suggests that falls may be an early marker of mobility
deterioration associated with disease progression [9, 10].
Rehabilitation interventions which improve balance and
physical activity and decrease the risk of falls may slow
this deterioration, providing a persuasive argument to
prioritise provision of effective physical management
strategies. However, there is currently minimal evidence-
based guidance to inform optimal mobility management
and none to inform falls management in people with
progressive MS. Whilst evidence is available for older
people and those with other neurological conditions,
research suggests that translating existing interventions
to pwMS is likely to be ineffective [20, 21]. Small, limited
duration studies have evaluated single elements of MS
balance and falls interventions, individually demonstrat-
ing short-term improvements in mobility, balance or
falls awareness [22–24], but these elements have not yet
been implemented or evaluated collectively. Moreover,
no studies have been confined to people with SPMS.
This feasibility trial begins to address all these issues.
Healthcare policy prioritises the need to empower and
support patients to self-manage [25]. ‘Balance Right in MS’
(BRiMS) is an innovative evidence-based, user-focused,
self-management exercise and education programme, de-
signed to improve safe mobility and reduce falls for
pwSPMS. It is critical to assess the delivery of this
programme and proposed evaluation methods prior to
undertaking a definitive trial to assess its effectiveness and
cost effectiveness.
Following Medical Research Council (MRC) Guide-
lines [26], this feasibility trial will aid the planning of an
anticipated definitive, multi-centre randomised con-
trolled trial (RCT) which will compare BRiMS plus usual
care with usual care alone in improving mobility and
quality of life (QoL), and reducing falls in people with
SPMS. This feasibility trial will provide the necessary
data and operational experience to inform the conduct
and finalise the design of a definitive trial so that it can
be successfully delivered with confidence. Ultimately,
this will add significantly to the evidence by reporting
results of a robust RCT of a manualised, complex
intervention.
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Methods
Trial design
This is a pragmatic, multi-centre, feasibility RCT with
blinded outcome assessment. Figure 1 shows the
planned participant pathway.
Trial settings
Four healthcare sites will be involved in this multi-
centre RCT, which is based in two geographical regions
of the UK: South West Peninsula (England) and Ayrshire
(Scotland). A full list of study sites is available via
www.brims.org.uk.
Participants
Sample size
As this is a feasibility trial, the more usual sample size
calculation, based on considerations of power for detect-
ing a between-group clinically meaningful difference in a
primary clinical outcome, is not appropriate [27]. In-
stead, the aim is to provide robust estimates of the likely
rates of recruitment and follow-up, as well as provide es-
timates of the variability of the proposed primary and
secondary outcomes to inform sample size calculations
for the planned definitive trial. Therefore, we aim to re-
cruit a total of 60 participants across the two regions (40
in the South West and 20 in Ayrshire) over 6 months.
An estimated 240 people will need to be screened to
achieve this sample size. From other studies in similar
settings, we anticipate that retention rates will be ap-
proximately 80% [28, 29]. With our intended sample size
of 60 participants, we will be able to estimate the overall
retention rate with precision of at least ±13%, and if the
6-month follow-up rate is around 80%, this estimate will
have precision of around ±10%. Assuming a non-
differential 6-month follow-up rate of 80%, this should
provide follow-up outcome data on a minimum of 24
participants in each of the allocated trial arms.
Inclusion criteria
The trial population will comprise individuals with a
confirmed diagnosis of MS as has been determined by a
neurologist according to revised McDonald’s criteria
[30], and who are in the secondary progressive phase.
Participants will:
 Be aged ≥18 years
 Be willing and able to understand/comply with all
trial activities
 Score ≥4.0 ≤ 7.0 on the Expanded Disability Status
Scale, i.e. people who have some mobility
impairment, but who are ambulant for at least a
proportion of the time
 Self-report two or more falls in the past 6 months
 Be willing and able to travel to local sites for blinded
outcome assessments and BRiMS programme
sessions
 Have access to a computer or tablet and to the
internet
Exclusion criteria
Potential participants will be excluded if they:
 Have relapsed/received steroid treatment within the
last month (patient-reported relapse is defined as
‘the appearance of new symptoms, or the return of
old symptoms, for a period of 24 h or more—in the
absence of a change in core body temperature or
infection’) [31]
 Have had any recent changes in disease-modifying
therapies; specifically, if they have ever had previous
treatment with alemtuzemab; are within 6 months
of ceasing nataluzimab; or are within 3 months of
ceasing any other MS disease-modifying drug
Fig. 1 Participant pathway
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 Have participated in a falls management programme
within the past 6 months
 Report co-morbidities which may influence their
ability to participate safely in the programme or are
likely to impact on the trial (e.g. uncontrolled
epilepsy).
 Are participating in a concurrent interventional
study
Identification and recruitment of participants will be
via several routes, including identification by healthcare
professionals, screening MS databases and promotion
via MS support groups and newsletters. This will be sup-
ported by National Institute for Health Research (NIHR)
Clinical Research Network staff at each site.
Randomisation and allocation concealment
The inclusion of group-based elements as part of the
intervention necessitates the confirmed participation of
a sufficient number of participants within a recruiting
site before randomisation occurs. There are four sites
where the intervention will be delivered. Once recruited,
participants will ideally be randomised in blocks of 10,
but the process can accommodate some flexibility within
the limits 8–12 participants in each block. Randomisa-
tion will be undertaken when a sufficient number of
individuals from a recruiting site have consented, indi-
cated that they are able to attend the same BRiMS group
(location, timing, should they be randomised to receive
it), and complete baseline data have been collected. The
decision to declare a block complete will be made by the
research therapist in collaboration with the Trial Co-
ordinator, Chief Investigator and local UK Clinical
Research Collaboration registered Clinical Trials Unit
(CTU) (Registration number 31). Randomisation will be
undertaken a minimum of 3 and a maximum of 7 days
prior to the commencement of the BRiMS programme
delivery (for each block).
When the block size from a recruiting site consists of
8–12 participants, the participants will be randomised to
the intervention or control group, using block simultan-
eous randomisation. The randomisation will be 1:1 when
the block consists of an even number of participants,
and when the block consists of an odd number of
participants, the allocation ratio will be in favour of the
intervention group in order to maximise recruitment
potential and learning opportunities in this feasibility
trial. Participants in a block will be numbered in the
order in which they were first entered onto the trial
website. The randomisation process will follow a strict
and auditable protocol. Randomisation will take place
after completion of all baseline assessments by the CTU
Trial Manager via a secure web-based system. The
randomised allocations will be computer-generated by
the CTU in conjunction with an independent statisti-
cian, in accordance with the CTU’s standard operating
procedure. The randomisation list and the programme
that generated it will be stored in a secure network loca-
tion within the CTU, accessible only to those responsible
for provision of the randomisation system.
After randomisation has taken place, an automatic
email will be sent by the CTU to the NHS Therapist
leading the BRiMS programme locally and to the rele-
vant Principal Investigator to notify them of each partici-
pant’s allocated group. Notification that randomisation
has taken place (but no details regarding individual par-
ticipant’s allocated group) will also be sent to the rele-
vant research therapist and to the CI.
Access to the randomisation code and allocation list
will be confined to the CTU data programmer; no one
else in the trial team will be aware of allocated trial arms
until formal randomisation is completed, hence main-
taining effective concealment. Following randomisation,
only appropriate members of the trial team will be aware
of participants’ allocations to intervention or control
group; the blinded research therapists will not have ac-
cess to treatment allocation.
Blinding
Due to the nature of the intervention, trial participants
and treating physiotherapists are unable to be blinded.
However, the assessors who are undertaking the out-
come assessments will be blinded to participant alloca-
tions. The initial baseline assessment will be undertaken,
following written informed consent obtained by the
research therapist, prior to randomisation. Every effort
will be made to ensure the two follow-up assessments
(at 15 and 27 weeks post-randomisation) remain blinded.
At each assessment time point, the assessor will be
asked to record if they were un-blinded to group alloca-
tion, and if so, the reasons for this.
Interventions
The BRiMS programme is delivered as a 13-week
therapy-led personalised education and exercise inter-
vention. It is structured to maximise the development of
self-efficacy and support participant engagement. BRiMS
aims to address modifiable fall risk factors such as poor
balance and mobility and enable self-management by
the use of individualised mobility, safety and falls risk
management strategies.
The development of BRiMS has been informed by the
MRC framework for the development and evaluation of
complex interventions [26] through a comprehensive
programme of research [9, 11, 32–34] and input from
internationally recognised experts [23, 35].
BRiMS includes a strong focus on home-based activ-
ities, supported by online resources and three group
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sessions interspersed over the duration of the
programme. The programme also includes two ‘one-to-
one’ sessions (in weeks 1 and 2) to enable individualised
assessment, goal planning and development of exercise
plans. A home-based online work package overarches
the programme, supporting both educational and exer-
cise components and enabling participants to personalise
the programme and apply the activities in their daily
lives from the outset (www.brims.org.uk). Developing
and supporting motivation is addressed throughout by
using innovative functional imagery techniques [36] to
supplement established motivational techniques.
Whilst the BRiMS programme is manualised, it is
structured to enable tailoring of the components to meet
the individual needs of participants (Fig. 2).
The BRiMS education component aims to improve ex-
ercise self-efficacy and enhance the individual’s know-
ledge and skills about falls prevention and management
[37]. This is delivered through a mix of home and group
activities embedded throughout the course of the
programme. It utilises group brainstorming, problem
solving and action planning [38] and applies the princi-
ples of cognitive behavioural therapy (CBT). During
group sessions, peer modelling, vicarious learning, social
persuasion and guided mastery are used to boost self-
efficacy [39]. Activities which encourage the setting and
imagery of short-term exercise goals are employed to
boost desire to achieve them, and images of failure are
‘rescripted’ [40].
The BRiMS exercise component supports the partici-
pant to undertake at least 120 min of gait, balance and
functional training per week. It has been designed to be
predominantly home-based, with exercise planning and
progression undertaken in partnership between the par-
ticipant and programme leader. The group sessions in-
clude exercise activities to encourage peer support and
problem solving. Additionally, BRiMS integrates an on-
line exercise prescription resource [41] to support and
guide home-based practice (www.webbasedphysio.com).
Usual care
This feasibility trial will use a usual clinical care control
group. Whilst usual care varies across the country [42],
in those with SPMS, physiotherapy input is generally
provided when an event has caused a significant
deterioration in the person’s ability to function (e.g. a
respiratory infection or an injurious fall). The standard
physiotherapy care pathway usually comprises short
intermittent episodes of face-to-face intervention. Typic-
ally, presenting problems are managed (e.g. providing
mobility aids, a written home exercise programme and
advice) rather than focusing on the promotion of long-
term self-management strategies. In this trial, the usual
care received (including health/social care interventions
and medications) will be recorded within the health eco-
nomic assessment of resource utilisation. In this feasibil-
ity study, the therapists providing the intervention are
not involved in providing the control group with ‘usual
care’, thereby avoiding potential contamination.
Data collection and outcome measurements
Participant data will be collected during face-to face
visits and through the return of postal diaries (see Table 1
for details). All participants will attend for three trial
assessment visits undertaken by the blinded research
therapists at baseline, 15 weeks (±1 week) and 27 weeks
(±1 week) after randomisation. These dates allow the
delivery of the pre-scheduled BRiMS programme to be
completed prior to the first follow-up assessment. Devia-
tions from this schedule will be monitored and reported
on a protocol deviation form.
The following data will be collected during the trial:
A. Feasibility outcomes
Data from screening, recruitment and follow-up
logs will be used to generate realistic estimates of
eligibility, recruitment, consent and follow-up rates.
B. Clinical outcome measures
Standardised clinician-rated and patient self-
reported clinical outcomes, which have demon-
strated good reliability and validity in people with
MS, will be measured. Further, in the main, these
measures have been widely used in MS interven-
tional studies, which will enable comparison
between studies.
1. Possible primary outcomes for the definitive trial
Fig. 2 BRiMS programme activities
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Walking—Multiple Sclerosis Walking Scale–12
item (MSWS-12) Version 2.0 [43].
Health-related quality of life EuroQoL (EQ-5D-
5L) [44] and the 29-item Multiple Sclerosis Im-
pact Scale (MSIS-29) Version 2.0 [45], which
have been specified for use in health economic
analyses in MS studies [46].
2. Possible secondary outcomes for the definitive trial
Falls frequency and injury rates
Falls will be defined as “an unexpected event in
which you come to rest on the floor or ground
or lower level” [47]. In line with best practice
guidance, the number of falls, injurious falls and
associated use of medical services will be
recorded prospectively using a patient-
completed daily diary returned to the CTU in a
FREEPOST envelope on a fortnightly basis [48].
Activity level using an activity monitor
(activPAL™, Paltechnologies Ltd, Glasgow) [49].
Walking capacity using the two-minute walk
test (fastest speed) (2MWT). This has been
recommended as the standard objective walking
test to be used in MS interventional studies [50].
Balance using the Mini-Balance Evaluation Sys-
tems Test (Mini-BEST) [51] and the Functional
Reach Test (forwards and lateral) [52–54].
Fear of falling using the 16-item self-report Falls
Efficacy Scale (International) (FESi) [55]. This
has been recommended as the standard
objective measure of fear of falling by the Pre-
vention of Falls Network Europe [47].
Community integration using the self-report
Community Participation Indicators (CPI) [56].
This has been recommended as an objective
measure of participation for use in falls preven-
tion studies by the International MS Falls Pre-
vention Research Network [57].
C. Measures of adherence
Attendance at the five face-to-face sessions will be
recorded; adherence will be calculated as a percent-
age. Engagement in the home-based programme
(BRiMS online exercise package and educational
packages) will be recorded based on the partici-
pants' web-based activity and participant reported
information.
This information, alongside the data obtained from
qualitative interviews with participants (see E
below) will be used to evaluate levels of adherence
and to determine whether any amendments to the
programme are required to improve engagement.
D. Economic evaluation
Methods for the collection of resource use, cost,
and outcome data will be developed and tested in
preparation for an economic evaluation alongside a
full trial. Data on resource use associated with the
setup and delivery of the BRiMS intervention will
be collected via within trial reporting, including
participant level contact and non-contact time for
Table 1 Data collection and outcome measures
Outcome measure Baseline 15 weeks post-randomisation
(±1 week)
27 weeks post-randomisation
(±1 week)
Demographics and history x Randomisation to intervention or
control
Provide falls diaries x Returned by post every 2 weeks
EDSS x
MSWS-12vs2.0 x x x
MSIS-29vs2.0 x x x
EQ-5D-5L x x x
Falls frequency x x x
Activity monitoring 1 week 1 week 1 week
2-minute walk test x x x
Mini-BEST x x x
Functional Reach Test x x x
Falls Efficacy Scale x x x
Community Participation
Indicators
x x x
Participant Resource Use
questionnaire
x x x
Adverse events x x
Qualitative interviews x
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staffing input on delivery, equipment and consum-
able costs, training and supervision. Data on health
and social care resource use will be collected at par-
ticipant level using a Participant Resource Use (RU)
questionnaire, developed for this trial [58]. The EQ-
5D-5L will be used to estimate quality-adjusted life-
years (QALYs), and is the expected primary eco-
nomic endpoint (cost per QALY) in any future
evaluation. The MSIS-8D [59, 60], an MS-specific
preference-based (QALY) measure, will also be
used, as this is expected to be of value in future
sensitivity analyses.
E. Process evaluation
Process evaluation is a key part of the intervention
development process and will be guided by the
MRC Process Evaluation of Complex Interventions
Guidelines [61] and the National Institute of Health
Behaviour Change Consortium framework [62].
1. Standardisation and fidelity of the intervention
Two research therapists (employed specifically for
the trial) will undertake the blinded assessments
using standardised written protocols. Treating
therapists from each site will perform the
interventions as part of their NHS physiotherapy
role. For this feasibility trial, all treating therapists
will undertake a training session as a group. They
will receive a therapist manual that provides a clear
structure to each session, details the session
content and provides sample scripts. All treating
physiotherapists have access to the programme
website (containing comprehensive reference
materials and a closed therapist discussion forum)
to optimise fidelity to the intervention content and
approach. Treatment fidelity of a random sample of
a minimum of 25% of the delivered sessions will be
assessed using audio recordings of the session. This
sample will include at least two recordings of each
session type (1:1 assessment, home visit and group
sessions) and at least one session from each treating
therapist. The assessment of fidelity will be
undertaken by two members of the research team
who are independent from the intervention
delivery, using a checklist which has been informed
by the Dreyfus System for Assessing Skill
Acquisition [63] and an adaptation of the
Motivational Interviewing Treatment Integrity scale
[64]. Both reviewers will initially meet to discuss
the fidelity assessment process and their
expectations for each element of the checklist. They
will then independently rate the same recording
and compare and moderate their assessments prior
to undertaking further reviews. Any uncertainties in
further reviews will be resolved through discussion.
Safety monitoring
Throughout the trial, all possible precautions will
be taken to ensure participant safety and wellbeing.
Participants will be monitored for adverse events
and serious adverse events (defined according to
the Medicines for Human Use (Clinical Trials)
Regulations, 2004) [65] via completion of their daily
diaries and during follow-up assessments. Partici-
pants will be asked to report all adverse events in
their diaries, whether they are thought to be related
to the intervention or not. Diaries will be reviewed
on receipt for reports of adverse events and
responded to according to pre-defined adverse
event and serious adverse event reporting
procedures.
Retention rates and withdrawals
Each participant has the right to voluntarily
withdraw from the trial at any time, without
repercussions. This is distinct from participants in
the intervention group terminating their
involvement in the BRiMS programme.
(a)Discontinuation of the intervention
Participants in the intervention group may
choose to discontinue the BRiMS programme,
or may do so on the recommendation of a
health professional, for example following an
adverse event. Where appropriate, such
participants will be asked to continue to attend
blinded assessments as per protocol if this is
feasible.
(b)Withdrawal from the trial
Any participant may at any time after they have
consented decide that they no longer wish to be
part of the trial. This may be through personal
choice (i.e. they withdraw their consent) or in
consultation with a health professional, for
example where it becomes impossible to
provide outcome data or comply with any other
trial procedures for whatever reason. In
addition, a participant may be withdrawn
following a significant protocol deviation, such
as being randomised in error. In this event, the
decision as to whether they should be removed
from the trial completely or retained on an
intention to treat (ITT) basis will be made
through an independent adjudication by the
Trial Steering Committee (TSC) who are
blinded to group allocation [68].
2. Qualitative evaluation
The qualitative evaluation aims to:
 Assess the acceptability of the trial methods
(both trial arms)
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 Evaluate the acceptability of the intervention and
identify possible adaptations
 Identify the components of the intervention
perceived to be effective.
One-to-one telephone interviews with trial partici-
pants and a telephone focus group [66] with treating
therapists will be undertaken by the regional BRiMS trial
coordinators at the completion of the programme. A
purposive sample of 10 participants will include people
from different regions, different BRiMS intervention
groups and a sample of control arm participants. Partici-
pants will be contacted and a mutually convenient time
agreed to undertake a telephone interview within 2 weeks
of the completion of their final trial visit. All treating
therapists will be invited to participate in the telephone
focus group which will be convened within 1 month of
the completion of the final BRiMS programme delivery.
All interviews will be digitally recorded and transcribed
verbatim. The researchers will employ a reflexive ap-
proach throughout, utilising research diaries, field notes
and critical reflection [67].
Data analysis
In keeping with the aims of a feasibility study, a detailed
statistical analysis plan will be developed and approved
by the Trial Steering Committee, prior to final database
lock and analyses. For the final analysis, the trial statisti-
cian will be presented with a database by the CTU con-
taining a group code for each participant but not
identifying which group is which; only after the primary
analyses will the two groups be identified.
The analyses of the quantitative data will be in two
stages, with data summarised according to participants’
allocated trial arm. All analyses will be undertaken and
reported according to the recently published CONSORT
guidelines for pilot and feasibility trials [68].
Stage 1 will summarise the feasibility outcomes: data
from screening, recruitment and follow-up logs will be
used to generate realistic estimates of eligibility, recruit-
ment, consent and follow-up rates and presented in a
CONSORT flowchart. In addition, adherence data (e.g.
session attendance and exercise adherence) will be used
to contribute to the evaluation of the acceptability and
concordance to the BRiMS programme. Completion
rates will be estimated for each of the outcome measures
at each time point. All estimates will be accompanied by
appropriate confidence intervals, to allow assumptions
to be made in the planning of the definitive trial. The
baseline characteristics of individuals lost to follow-up
will be compared to those who complete the feasibility
trial to identify any potential bias.
Stage 2 will summarise the clinical outcomes data at
each time point. As it is inappropriate to use feasibility
trial data to formally test for between-group treatment
effects, the analyses will primarily be of a descriptive
nature [27, 69]. The CONSORT extension for reporting
of pilot and feasibility studies [68] and the CONSORT
extension for reporting of patient-reported outcomes
[70] will be followed. Descriptive statistics of the clinical
outcomes data will be produced for each trial arm.
Interval estimates of the potential intervention effects,
relative to usual care only, will be produced in the form
of a 95% confidence interval, to ensure that the effect size
subsequently chosen for powering the definitive trial is
plausible, but no formal hypothesis testing will be
undertaken [27].
Qualitative analysis
The qualitative analysis will employ a constructivist
paradigm, described as an approach which allows the
co-creation of understandings by respondent and re-
searcher [71]. The qualitative data will include tran-
scripts from one-to-one participant interviews, and the
health professional telephone focus group.
Anonymised transcribed data will be entered into
NVIVO software (QSR International, Southport, UK). A
pragmatic process of data immersion, coding and gener-
ation of initial themes will then be undertaken [72]. Sub-
sequently, these themes will be refined in discussion
with research team members to maximise credibility of
the process [73]. The rigour of the qualitative analysis
will be maximised through use of a range of techniques,
including exploration of contradictory evidence, re-
spondent validation, and constant comparison [74]. In
addition, interview and focus group participants will be
invited to review an initial draft to ensure the analysis
represents an accurate overview of participants’ views,
experiences and recommendations. Once this has been
verified, the data will be used to (where necessary) revise
the BRiMS Operational Manual and Trial Procedures.
Determining progression to the full trial
We shall progress to a full trial application if minimum
success criteria are achieved in key feasibility aims and
objectives, or if we can identify solutions to overcome
any identified issue. These criteria will be finalised in
discussion with the Trial Steering Committee, but are
likely to include:
 A minimum of 80% recruitment of the intended 60
participants within the 6-month recruitment
window
 A minimum of 80% completion rate of key outcome
measures (including follow-up)
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Data management, audit and monitoring
The CTU will be responsible for data management for
the study. Data will be recorded on study-specific data
collection forms by the blinded assessors, and on self-
completion forms by study participants. Completed
forms will be passed to the CTU and entered onto a
secure web-based database. All data will be double en-
tered and compared for discrepancies. Discrepant data
will be verified using the original paper data sheets.
Data will be collected and stored in accordance with
the Data Protection Act 1998 and will be accessible for
the purposes of monitoring, auditing, or at the request
of the regulatory agency.
Trial oversight
There are three committees involved in the setup, man-
agement and oversight of this trial: the Trial Manage-
ment Group (TMG), the Trial Steering Committee
(TSC) and the Data Monitoring Committee (DMC).
The TMG comprises those individuals involved in the
development of the protocol and the day-to-day running
of the study. The responsibility of this group is to ensure
all practical details of the trial are progressing, and
everyone within the trial understands them. This in-
cludes monitoring adverse events, recruitment and
attrition rates, the project timeline and finances. It will
also include responsibility for the release of the trial
results and publications. The TMG will meet approxi-
mately monthly.
The TSC is responsible for overseeing the conduct of
the trial and comprises a group of experienced trialists
with majority independent representation. The TSC will
meet before the start of the trial and subsequently at
least annually. In addition, the TSC and DMC will
receive a quarterly report of adverse events, and a
telephone conference/additional face-to-face meeting will
be instigated by the chair of either group, or the chief
investigator (CI) should any issues need to be discussed.
The DMC comprises an independent statistician and
two experienced clinical trialists, one of whom will be
the chair. This committee will be independent of the
study organisers and the TSC; the DMC will maintain
the interests of trial participants, with particular refer-
ence to safety, and will report to the chair of the TSC. It
is anticipated that the members will meet once to agree
terms of reference and subsequently at a schedule to be
agreed with the TSC.
Ethics
The trial will be conducted in accordance with the
Declaration of Helsinki, 1996 [75]; the principles of
Good Clinical Practice, and the Department of Health
Research Governance Framework for Health and Social
Care, 2005 [76]. All ethical approvals will be in place
prior to the commencement of trial recruitment activities
(see declarations section).
Dissemination plan
The results of this feasibility trial will inform the design
of the anticipated definitive trial, rather than directly
inform clinical decision making, since clinical and cost
effectiveness cannot be determined at this level. Hence,
dissemination, regardless of outcome of this feasibility
trial, will focus on publication of the feasibility out-
comes, and related methodological issues, in open access
peer-reviewed journals.
On completion, the full study report will be accessible
on the study website (www.brims.org.uk) and via the
funding body website, as will the full protocol. This
protocol (Version 3.0, dated 07 Dec 2016) has been
written in line with SPIRIT Guidelines [77]. Similarly,
the Consolidated Standards of Reporting Trials (CON-
SORT) [68, 78] and the Template for Intervention
Description and Replication (TiDIER) Guidelines [79]
will be reviewed prior to submitting future publications
of the trial results. Authorship of articles will be by the
study team; professional writers will not be used.
Results of this feasibility trial will be presented at na-
tional and international conferences to engender enthu-
siasm for the potential future trial. Summaries will be
posted on to the websites/newsletters of the organisa-
tions who were involved in the recruitment process. In
addition, all participants will be offered a lay summary
of results and a clinically oriented summary will be
provided to recruiting centres. A key output will be an
application for funding for a definitive trial, if the results
of the feasibility trial meet the criteria for progression.
Discussion
The importance of developing interventions to support
pwMS to maintain their mobility and manage falls has
been highlighted by service users and providers, and in
practice guidelines [1, 6, 19]. The BRiMS intervention
has been developed with the aim of addressing this
important issue; however, a full evaluation of its effect-
iveness is essential to inform evidence-based clinical
decision making. Best practice guidance emphasises the
need to thoroughly test the feasibility and acceptability
of both interventions and trial evaluation procedures
prior to undertaking a full-scale assessment of effective-
ness [26]. This feasibility trial will provide important
insights into the practicality of running a full-scale trial
to evaluate BRiMS, including providing estimates of: re-
cruitment, attrition, adherence, baseline scores, standard
deviations and completion rates of the measures. It will
also enable us to assess the acceptability of the interven-
tion and of participating in the trial from the participant
and health professional perspective, and the process of
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delivering BRiMS, to finalise a protocol for use in the
definitive trial. Whilst the trial has been developed
according to best practice guidance, the methodology is
not without potential limitations. For example, the use
of active and attention-matched control groups has been
debated in the literature [80, 81]; in this trial, the lack of
evidence to inform the selection of an active comparator,
along with the cost implications of including a third
attention-matched group, led to the pragmatic decision
to utilise a usual care control group.
One potential scheduling issue that we aim to test is the
feasibility of the relatively short (minimum 3 days) time-
scale between randomisation and commencement of the
BRiMS programme for those allocated to the intervention
group, necessitated by the group elements within the
BRiMS programme. Whilst considerable thought has been
given to minimising this challenge, for example by
pre-scheduling the BRiMS programme dates, qualitative
feedback from participants and treating therapists will be
important to finalise this aspect of a future full-scale trial.
This trial specifically targets people with SPMS, whose
MS type and level of impaired mobility often makes
them ineligible to participate in clinical trials, and for
whom medical intervention is limited. Whilst we have
estimates of potential recruitment and retention rates
from other studies of similar interventions, these trials
included participants with a range of MS sub-types.
Therefore, it will be important to assess whether these
estimates are appropriate for people with SPMS who
may have more health issues which could impact on
their participation in trials.
Trial status
Recruitment commenced mid-January 2017.
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